{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-1976-N-0031\" and posted_year = 2016 sorted by posted_date descending", "rows": [["FDA-1976-N-0031-0223", "FDA", "FDA-1976-N-0031", "Letter from Florida Pharmacy Association", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:02:34Z", null, 0, 0, "090000648051bb7c"], ["FDA-1976-N-0031-0211", "FDA", "FDA-1976-N-0031", "Exhibit 5 re Letter from Warner-Lambert Company - Allergy & Asthma Clinic, P.C. to Warner-Chilcott dated February 15, 1977", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:44:32Z", null, 0, 0, "090000648051bb68"], ["FDA-1976-N-0031-0226", "FDA", "FDA-1976-N-0031", "Amendment from Vick's Division of Research and Development re Supplement 11 from  Vick's Division of Research and Development on 06/07/1979", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:03:31Z", null, 0, 0, "090000648051bb80"], ["FDA-1976-N-0031-0246", "FDA", "FDA-1976-N-0031", "Supporting material re Amendment from Smith Kline & French Laboratories (REDACTED)", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T19:24:31Z", null, 0, 0, "09000064822aefbf"], ["FDA-1976-N-0031-0130", "FDA", "FDA-1976-N-0031", "Final Order, Opinion of the Commission, and Initial Decision by Federal Trade Commission in the Matter of Warner-Lambert Company", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T17:42:25Z", null, 0, 0, "090000648228ec92"], ["FDA-1976-N-0031-0256", "FDA", "FDA-1976-N-0031", "Acknowledgment Letter from FDA/CDER to Clifford, Glass, McTwain & Tinney", "Other", "Acknowledgement Letter/Receipt", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T20:05:30Z", null, 0, 0, "0900006481ce5694"], ["FDA-1976-N-0031-0238", "FDA", "FDA-1976-N-0031", "Letter from FDA/HFD-513 to Pfizer Pharmaceuticals", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:20:55Z", null, 0, 0, "090000648051bb8e"], ["FDA-1976-N-0031-0131", "FDA", "FDA-1976-N-0031", "Official Transcript of Proceedings Before the Federal Trade Commission (1 of 2)", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T17:42:34Z", null, 0, 0, "090000648228ec93"], ["FDA-1976-N-0031-0227", "FDA", "FDA-1976-N-0031", "Answer from FDA re Amendment from Vick's Division of Research and Development re Supplement 11 from  Vick's Division of Research and Development on 06/07/1979", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:03:40Z", null, 0, 0, "09000064822abbb2"], ["FDA-1976-N-0031-0178", "FDA", "FDA-1976-N-0031", "Section III: Description of the D.A.T.A. System", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:17:52Z", null, 0, 0, "090000648229b47c"], ["FDA-1976-N-0031-0215", "FDA", "FDA-1976-N-0031", "Letter from Vick Divisions Research and Development (Richardson-Merrell Inc.)", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:52:34Z", null, 0, 0, "090000648051bb71"], ["FDA-1976-N-0031-0146", "FDA", "FDA-1976-N-0031", "Request for Extension Comment from The Proprietary Association", "Other", "Request for Extension", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T17:52:05Z", null, 0, 0, "090000648051bb1e"], ["FDA-1976-N-0031-0220", "FDA", "FDA-1976-N-0031", "Letter from Vick Divisions Research and Development (Richardson-Merrell Inc.)", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:59:29Z", null, 0, 0, "090000648051bb76"], ["FDA-1976-N-0031-0206", "FDA", "FDA-1976-N-0031", "Supplement from Smith Kline Corporation (Vol. 1 of 6) re Data Supporting the Efficacy of Chlorpheniramine Maleate in Providing Symptomatic Relief of the ''Common Cold\"", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:35:27Z", null, 0, 0, "090000648051bb59"], ["FDA-1976-N-0031-0062", "FDA", "FDA-1976-N-0031", "Memorandum of Telephone Conversation from FDA/CDER", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T14:58:19Z", null, 0, 0, "090000648051babe"], ["FDA-1976-N-0031-0171", "FDA", "FDA-1976-N-0031", "Letter from Fisons Corporation to FDA/CDER", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:16:05Z", null, 0, 0, "090000648051bb3a"], ["FDA-1976-N-0031-0244", "FDA", "FDA-1976-N-0031", "Memorandum of Meeting Between FDA/CDER, Burroughs-Wellcome Co., Dow Chemical Co. and Schering Corp.", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:24:06Z", null, 0, 0, "090000648051bb98"], ["FDA-1976-N-0031-0194", "FDA", "FDA-1976-N-0031", "Answer from FDA/CDER to American Pharmaceutical Association", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:28:02Z", null, 0, 0, "090000648051bbc8"], ["FDA-1976-N-0031-0170", "FDA", "FDA-1976-N-0031", "Correction of Comment from The Proprietary Association", "Other", "Correction(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:15:53Z", null, 0, 0, "090000648051bb39"], ["FDA-1976-N-0031-0207", "FDA", "FDA-1976-N-0031", "Supplement from Smith Kline & French Laboratories", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:36:09Z", null, 0, 0, "090000648051bb5a"], ["FDA-1976-N-0031-0159", "FDA", "FDA-1976-N-0031", "Correction from Miles Laboratories, Inc", "Other", "Correction(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T17:55:45Z", null, 0, 0, "090000648051bb2b"], ["FDA-1976-N-0031-0091", "FDA", "FDA-1976-N-0031", "Notice of Decision on Diphenhydramine As An Antitussive", "Notice", "General Notice", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T15:19:55Z", null, 0, 0, "0900006481cfac60"], ["FDA-1976-N-0031-0147", "FDA", "FDA-1976-N-0031", "Answer from FDA/CDER re Request for Extension Comment from The Proprietary Association", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2017-11-29T07:09:41Z", null, 0, 0, "090000648227cf04"], ["FDA-1976-N-0031-0109", "FDA", "FDA-1976-N-0031", "Table of Contents re Comment from Vick Divisions Research, Vick Chemical Company", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:48:36Z", null, 0, 0, "0900006482278091"], ["FDA-1976-N-0031-0113", "FDA", "FDA-1976-N-0031", "List of Attachments re Comment from Vick Divisions Research, Vick Chemical Company", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T16:31:40Z", null, 0, 0, "0900006482278751"], ["FDA-1976-N-0031-0175", "FDA", "FDA-1976-N-0031", "Supporting material re Supplement from Graduate Research Laboratories, Inc. - Table of Contents", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:17:35Z", null, 0, 0, "090000648229b479"], ["FDA-1976-N-0031-0177", "FDA", "FDA-1976-N-0031", "Section II: Automated Antitussive Instruments -- A Literature Review", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:17:47Z", null, 0, 0, "090000648229b47b"], ["FDA-1976-N-0031-0225", "FDA", "FDA-1976-N-0031", "Letter from Warner-Lambert Company to FDA", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:03:00Z", null, 0, 0, "090000648051bb7e"], ["FDA-1976-N-0031-0232", "FDA", "FDA-1976-N-0031", "Answer from FDA/CDER to Warner-Lambert Company", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:05:31Z", null, 0, 0, "0900006480f1773d"], ["FDA-1976-N-0031-0140", "FDA", "FDA-1976-N-0031", "Request for Extension from Graduate Research Laboratories, Inc.", "Other", "Request for Extension", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T17:50:01Z", null, 0, 0, "090000648051bb18"], ["FDA-1976-N-0031-0166", "FDA", "FDA-1976-N-0031", "Over-The Counter-Drugs: Notice of Decision on Theophylline as a Single Ingredient", "Notice", "General Notice", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:05:24Z", null, 0, 0, "090000648051bb35"], ["FDA-1976-N-0031-0210", "FDA", "FDA-1976-N-0031", "Letter from Warner-Lambert Company", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:44:15Z", null, 0, 0, "090000648051bb69"], ["FDA-1976-N-0031-0224", "FDA", "FDA-1976-N-0031", "Memorandum of Telephone Conversation Between FDA/CDER and Warner Lambert", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:02:47Z", null, 0, 0, "090000648051bb7d"], ["FDA-1976-N-0031-0242", "FDA", "FDA-1976-N-0031", "Letter from National Pharmaceutical Mfg. Co. to FDA/CDER", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:23:36Z", null, 0, 0, "090000648051bb95"], ["FDA-1976-N-0031-0169", "FDA", "FDA-1976-N-0031", "Answer re Request for Extension from Graduate Research Laboratories Inc.", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:15:43Z", null, 0, 0, "09000064822948e4"], ["FDA-1976-N-0031-0222", "FDA", "FDA-1976-N-0031", "Letter from Bristol-Myers Products (A Division of Bristol-Myers Company) to FDA", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:02:19Z", null, 0, 0, "090000648051bb7a"], ["FDA-1976-N-0031-0254", "FDA", "FDA-1976-N-0031", "Letter from FDA/CDER to The Dow Chemical Company", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:32:56Z", null, 0, 0, "090000648051bba4"], ["FDA-1976-N-0031-0205", "FDA", "FDA-1976-N-0031", "Supplement from Schering Corporation", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:34:22Z", null, 0, 0, "090000648051bb58"], ["FDA-1976-N-0031-0213", "FDA", "FDA-1976-N-0031", "Supplement from Vick's Division of Research and Development", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:51:58Z", null, 0, 0, "090000648051bb6f"], ["FDA-1976-N-0031-0245", "FDA", "FDA-1976-N-0031", "Amendment from Smith Kline & French Laboratories", "Other", "Amendment", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:24:19Z", null, 0, 0, "090000648051bb99"], ["FDA-1976-N-0031-0255", "FDA", "FDA-1976-N-0031", "Letter from FDA/CDER to Schering-Plough Corporation", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:33:07Z", null, 0, 0, "090000648051bba5"], ["FDA-1976-N-0031-0176", "FDA", "FDA-1976-N-0031", "Section I: Overview", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:17:41Z", null, 0, 0, "090000648229b47a"], ["FDA-1976-N-0031-0221", "FDA", "FDA-1976-N-0031", "Letter from Vick Divisions Research and Development (Richardson-Merrell Inc.)", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:59:53Z", null, 0, 0, "090000648051bb77"], ["FDA-1976-N-0031-0064", "FDA", "FDA-1976-N-0031", "Request for Extension from Richardson-Merrell Inc.", "Other", "Request for Extension", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T14:58:49Z", null, 0, 0, "090000648051bac0"], ["FDA-1976-N-0031-0029", "FDA", "FDA-1976-N-0031", "Memorandum of Telephone Conversation Between Tenny P. Neprud, Compliance Regulations Policy Staff, ACC and  Harold F. O' Keefe, Arthur A. Checchi, Inc.", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T13:16:21Z", null, 0, 0, "090000648051ba67"], ["FDA-1976-N-0031-0195", "FDA", "FDA-1976-N-0031", "Over-The-Counter Drugs Proposed Monograph for OTC Cold, Cough, Allergy, Bronchodilator and Antiasthmatic Products; Amendment", "Notice", "General Notice", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", "1977-12-28T04:59:59Z", "2016-10-14T18:28:17Z", null, 0, 0, "090000648051bb4e"], ["FDA-1976-N-0031-0132", "FDA", "FDA-1976-N-0031", "Official Transcript of Proceedings Before the Federal Trade Commission (2 of 2)", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T17:42:41Z", null, 0, 0, "090000648228ec94"], ["FDA-1976-N-0031-0097", "FDA", "FDA-1976-N-0031", "Supporting material re Comment from Joint Council of Socio-Economics of Allergy - Position Statement on Over-The-Counter Sales of Antihistamine and Decongestant Drugs, by Joint Council of Socio-Economics of Allergy Committee to the FDA", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:21:09Z", null, 0, 0, "090000648227f4e4"], ["FDA-1976-N-0031-0107", "FDA", "FDA-1976-N-0031", "Tab 1: Cold Symptoms Grouped as to Responsiveness to Three Categories of Pharmacological Activity", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:33:23Z", null, 0, 0, "090000648227fb1f"], ["FDA-1976-N-0031-0106", "FDA", "FDA-1976-N-0031", "Exhibit 1: Supporting material re Comment from Dorsey Laboratories", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:33:17Z", null, 0, 0, "090000648227fb1e"], ["FDA-1976-N-0031-0257", "FDA", "FDA-1976-N-0031", "Correction from Vick Divisions Research and Development", "Other", "Correction(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T20:06:16Z", null, 0, 0, "0900006481ce2563"], ["FDA-1976-N-0031-0219", "FDA", "FDA-1976-N-0031", "Supplement from Vick Divisions Research and Development", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:58:51Z", null, 0, 0, "09000064822a38b6"], ["FDA-1976-N-0031-0204", "FDA", "FDA-1976-N-0031", "Answer from FDA/CDER re Comment from Bristol-Myers Products", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:32:55Z", null, 0, 0, "090000648228fb80"], ["FDA-1976-N-0031-0189", "FDA", "FDA-1976-N-0031", "Supporting material re Reply Comment from Merrell-National Laboratories - 2/9/77 letter to Dr. Parks", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:23:13Z", null, 0, 0, "090000648229351b"], ["FDA-1976-N-0031-0037", "FDA", "FDA-1976-N-0031", "Memorandum of Meeting between FDA/CDER and representatives of Parke, Davis and Company", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T13:39:05Z", null, 0, 0, "090000648051ba9f"], ["FDA-1976-N-0031-0202", "FDA", "FDA-1976-N-0031", "Petition for Reconsideration from Parke-Davis & Company", "Other", "Petition for Reconsideration", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:30:14Z", null, 0, 0, "090000648051bb56"], ["FDA-1976-N-0031-0126", "FDA", "FDA-1976-N-0031", "Supplement from Ohio Society of Allergy and Immunology", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T17:37:38Z", null, 0, 0, "090000648051bb0d"], ["FDA-1976-N-0031-0193", "FDA", "FDA-1976-N-0031", "Answer from FDA/CDER to Freida Rasmussen", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:27:50Z", null, 0, 0, "090000648051bbc9"], ["FDA-1976-N-0031-0110", "FDA", "FDA-1976-N-0031", "Comment from Vick Divisions Research, Vick Chemical Company (Vol. 2 of 8)", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T16:08:43Z", null, 0, 0, "0900006481cdcc41"], ["FDA-1976-N-0031-0253", "FDA", "FDA-1976-N-0031", "Letter from FDA/CDER to Burroughs Wellcome Company", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:32:45Z", null, 0, 0, "090000648051bba3"], ["FDA-1976-N-0031-0168", "FDA", "FDA-1976-N-0031", "Request for Extension from Graduate Research Laboratories Inc.", "Other", "Request for Extension", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:15:36Z", null, 0, 0, "090000648051bb38"], ["FDA-1976-N-0031-0076", "FDA", "FDA-1976-N-0031", "Tab 2: Composition", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:10:47Z", null, 0, 0, "090000648051bad3"], ["FDA-1976-N-0031-0239", "FDA", "FDA-1976-N-0031", "Memorandum from FDA/HFD-510 to FDA/HFA-305", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:22:20Z", null, 0, 0, "090000648051bbc0"], ["FDA-1976-N-0031-0237", "FDA", "FDA-1976-N-0031", "Memorandum from FDA/HFD-510 to FDA/HFA-305", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:07:28Z", null, 0, 0, "090000648051bb8d"], ["FDA-1976-N-0031-0077", "FDA", "FDA-1976-N-0031", "Tab 6: Summary", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:11:08Z", null, 0, 0, "090000648051bace"], ["FDA-1976-N-0031-0111", "FDA", "FDA-1976-N-0031", "Background Material re Comment from Vick Divisions Research, Vick Chemical Company (Vol. 6 of 8)", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T16:23:44Z", null, 0, 0, "0900006481cdd5b0"], ["FDA-1976-N-0031-0179", "FDA", "FDA-1976-N-0031", "Section IV: Validation of the D.A.T.A. System", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:17:59Z", null, 0, 0, "090000648229b47d"], ["FDA-1976-N-0031-0235", "FDA", "FDA-1976-N-0031", "Supporting material re Comment from Bristol-Myers - Investigator Letters", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T19:07:04Z", null, 0, 0, "09000064822adc34"], ["FDA-1976-N-0031-0214", "FDA", "FDA-1976-N-0031", "Answer from FDA re Supplement from Vick's Division of Research and Development", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:52:11Z", null, 0, 0, "09000064822a0d57"], ["FDA-1976-N-0031-0218", "FDA", "FDA-1976-N-0031", "Supplement from Vick Divisions Research and Development", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:54:04Z", null, 0, 0, "0900006481cdeec9"], ["FDA-1976-N-0031-0251", "FDA", "FDA-1976-N-0031", "Petition Approval from FDA/CDER to Marion Laboratories, Inc.", "Other", "Approval", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:26:03Z", null, 0, 0, "090000648051bba1"], ["FDA-1976-N-0031-0230", "FDA", "FDA-1976-N-0031", "Supplement from A. H. Robins Company", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:04:22Z", null, 0, 0, "090000648051bb85"], ["FDA-1976-N-0031-0243", "FDA", "FDA-1976-N-0031", "Petition for Stay of Action from Dow Chemical U. S. A.", "Other", "Petition for Reconsideration", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:23:50Z", null, 0, 0, "090000648051bb97"], ["FDA-1976-N-0031-0174", "FDA", "FDA-1976-N-0031", "Supplement from Graduate Research Laboratories, Inc.", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:17:16Z", null, 0, 0, "090000648051bb3f"], ["FDA-1976-N-0031-0252", "FDA", "FDA-1976-N-0031", "Petition Approval from FDA/CDER to Johnson and Johnson", "Other", "Approval", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:29:57Z", null, 0, 0, "090000648051bba2"], ["FDA-1976-N-0031-0197", "FDA", "FDA-1976-N-0031", "Supplement from Massachusetts College of Pharmacy", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:28:48Z", null, 0, 0, "090000648051bb50"], ["FDA-1976-N-0031-0063", "FDA", "FDA-1976-N-0031", "Request for Extension from The Proprietary Association", "Other", "Request for Extension", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T14:58:39Z", null, 0, 0, "090000648051babf"], ["FDA-1976-N-0031-0112", "FDA", "FDA-1976-N-0031", "Background Material re Comment from Vick Divisions Research, Vick Chemical Company (Vol. 8 of 8)", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T16:30:42Z", null, 0, 0, "0900006482278096"], ["FDA-1976-N-0031-0241", "FDA", "FDA-1976-N-0031", "Petition for Stay of Action from Marion Laboratories, Inc.", "Other", "Petition for Reconsideration", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:23:05Z", null, 0, 0, "090000648051bb93"], ["FDA-1976-N-0031-0229", "FDA", "FDA-1976-N-0031", "Answer from FDA re Supplement from A. H. Robins Company", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:04:00Z", null, 0, 0, "09000064822ac9da"], ["FDA-1976-N-0031-0075", "FDA", "FDA-1976-N-0031", "Tab 1a: Current Labels/Labeling", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T15:10:32Z", null, 0, 0, "090000648051bad5"], ["FDA-1976-N-0031-0190", "FDA", "FDA-1976-N-0031", "Supporting material re Reply Comment from Merrell-National Laboratories - Doxylamine Succinate Bibliography", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T18:23:25Z", null, 0, 0, "090000648229351d"], ["FDA-1976-N-0031-0217", "FDA", "FDA-1976-N-0031", "Memorandum of Telephone Conversation Between FDA/CDER and Warner-Lambert Company", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T18:53:31Z", null, 0, 0, "090000648051bb73"], ["FDA-1976-N-0031-0240", "FDA", "FDA-1976-N-0031", "Petition for Reconsideration from Johnson and Johnson", "Other", "Petition for Reconsideration", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:22:52Z", null, 0, 0, "090000648051bb91"], ["FDA-1976-N-0031-0228", "FDA", "FDA-1976-N-0031", "Supplement from A. H. Robins Company", "Other", "Supplement (SUP)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:03:52Z", null, 0, 0, "090000648051bb81"], ["FDA-1976-N-0031-0163", "FDA", "FDA-1976-N-0031", "Letter from Louisiana State University Medical Center to FDA/CDER", "Other", "Letter(s)", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T17:58:44Z", null, 0, 0, "090000648051bb32"], ["FDA-1976-N-0031-0030", "FDA", "FDA-1976-N-0031", "Reference from U. S. Department of Health , Education and Welfare", "Supporting & Related Material", "Reference (internal unless indicated)", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T13:16:40Z", null, 0, 0, "090000648051ba9c"], ["FDA-1976-N-0031-0114", "FDA", "FDA-1976-N-0031", "Answer from FDA/CDER (formerly Bureau of Drugs) to Vick Divisions Research and Development", "Other", "Answer", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T16:34:39Z", null, 0, 0, "0900006480a77ae8"], ["FDA-1976-N-0031-0248", "FDA", "FDA-1976-N-0031", "Memorandum of Telephone Conversation Between FDA/CDER and Johnson & Johnson", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T19:25:12Z", null, 0, 0, "090000648051bb9d"], ["FDA-1976-N-0031-0061", "FDA", "FDA-1976-N-0031", "Memorandum of Telephone Conversation from FDA/CDER", "Other", "Memorandum", "2016-10-14T04:00:00Z", 2016, 10, "2016-10-14T04:00:00Z", null, "2016-10-14T14:56:37Z", null, 0, 0, "090000648051babd"], ["FDA-1976-N-0031-0258", "FDA", "FDA-1976-N-0031", "Background material re Administrative File for the Statement of The Advisory Review Panel on OTC Miscellaneous External Drug Products Concerning OTC Drugs Containing Campher", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T20:09:14Z", null, 0, 0, "09000064822ae4cd"], ["FDA-1976-N-0031-0236", "FDA", "FDA-1976-N-0031", "Supporting material re Comment from Bristol-Myers - Statistical Report", "Supporting & Related Material", "Background Material", "2016-10-14T04:00:00Z", 2016, 10, null, null, "2016-10-14T19:07:11Z", null, 0, 0, "09000064822adc35"], ["FDA-1976-N-0031-0027", "FDA", "FDA-1976-N-0031", "Notice of Proposed Rule re Over-The-Counter Drugs; Establishment of a Monograph for OTC Cold, Cough, Allergy, Bronchodilator and Antiasthmatic Products (Page 324 -423)\u2028", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2016-09-26T04:00:00Z", 2016, 9, "2016-09-26T04:00:00Z", "1976-12-09T04:59:59Z", "2016-09-26T18:16:23Z", null, 0, 0, "0900006481e508da"], ["FDA-1976-N-0031-0028", "FDA", "FDA-1976-N-0031", "Notice of Proposed Rule re Over-The-Counter Drugs; Establishment of a Monograph for OTC Cold, Cough, Allergy, Bronchodilator and Antiasthmatic Products (Part 926-940)\u2028", "Proposed Rule", "Notice of Proposed Rulemaking (NPRM)", "2016-09-26T04:00:00Z", 2016, 9, "2016-09-26T04:00:00Z", "1976-12-09T04:59:59Z", "2016-09-26T18:26:14Z", null, 0, 0, "0900006481e4f035"]], "truncated": false, "filtered_table_rows_count": 94, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-1976-N-0031", "p1": "2016"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016", "results": [{"value": "FDA", "label": "FDA", "count": 94, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016", "results": [{"value": "Other", "label": "Other", "count": 63, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&document_type=Other", "selected": false}, {"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 26, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&document_type=Notice", "selected": false}, {"value": "Proposed Rule", "label": "Proposed Rule", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&document_type=Proposed+Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016", "results": [{"value": 2016, "label": 2016, "count": 94, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet=comment_start_date"}, {"name": "comment_end_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet=comment_end_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-1976-N-0031&posted_year=2016&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 2469.558192999102, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}